HOTH
Hoth Therapeutics Inc
NASDAQ: HOTH · HEALTHCARE · BIOTECHNOLOGY
$0.71
-2.70% today
Updated 2026-04-29
Market cap
$13.67M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-0.90
Dividend yield
—
52W range
$0 – $2
Volume
3.1M
Hoth Therapeutics Inc (HOTH) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — | — | — | — | — | — |
| Cost of revenue | $188.00 | $28252.00 | $31622.00 | $25871.00 | $46.87M | $66834.00 | — | — | — |
| Gross profit | $-188.00 | $-28252.00 | $-31622.00 | $-25871.00 | $-46.87M | $-66834.00 | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — | — |
| R&D | $586843.00 | $1.02M | $2.12M | $2.89M | $7.53M | $4.93M | $3.48M | $3.25M | $5.95M |
| SG&A | $320123.00 | $1.22M | $5.06M | $2.93M | $6.57M | $6.13M | $4.21M | $4.97M | $6.41M |
| Operating income | $-1.87M | $-2.50M | $-7.71M | $-7.30M | $-14.10M | $-11.07M | $-7.69M | $-8.22M | $-11.11M |
| Operating margin | — | — | — | — | — | — | — | — | — |
| EBITDA | $-2.02M | $-2.49M | $-7.71M | $-7.30M | $-14.31M | $-10.68M | $-153149.00 | $27132.00 | $-11.11M |
| EBITDA margin | — | — | — | — | — | — | — | — | — |
| EBIT | $-2.02M | $-2.50M | $-7.71M | $-7.30M | $-14.10M | $-21.74M | $-7.85M | $-8.19M | — |
| Interest expense | $0.00 | $0.00 | $0.00 | $0.00 | $212265.00 | $305409.00 | — | — | — |
| Income tax | $2.00 | $-159917.00 | $-10361.00 | $-205254.00 | $212265.00 | $305409.00 | $-7692.00 | — | — |
| Effective tax rate | -0.0% | 6.0% | 0.1% | 2.8% | -1.5% | -2.8% | 0.1% | 0.0% | 0.0% |
| Net income | $-2.02M | $-2.50M | $-7.69M | $-7.20M | $-14.31M | $-11.37M | $-7.85M | $-8.19M | $-12.47M |
| Net income growth (YoY) | — | -23.8% | -208.3% | +6.5% | -98.9% | +20.6% | +31.0% | -4.4% | -52.3% |
| Profit margin | — | — | — | — | — | — | — | — | — |